SCHEMBL20819031

SCHEMBL20819031

COc1cccc2oc(-c3c(O)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ARF6 P62330 5/20 0.37
▸ TNKS O95271 3/20 0.36
▸ TNKS2 Q9H2K2 3/20 0.36
▸ PARP2 Q9UGN5 2/20 0.36
▸ TSHR P16473 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ F2RL3 Q96RI0 2/20 0.34
▸ TOP2A P11388 1/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ APLNR P35414 1/20 0.33
▸ DHODH Q02127 1/20 0.33
▸ HTR3A P46098 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819079 0.92 TNKS (0.38) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20914203 0.91 TNKS (0.37) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20819069 0.91 TNKS (0.37) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20819040 0.90 TNKS (0.35) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20818975 0.90 TNKS (0.36) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20819052 0.90 ARF6 (0.37) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20913994 0.89 POLB (0.37) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20913986 0.89 TNKS (0.35) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20914091 0.89 TNKS (0.34) ARF6TNKSTNKS2PARP2TSHR
SCHEMBL20914023 0.88 F2RL3 (0.39) ARF6TNKSTNKS2PARP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
EP-3681888-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2020-07-22 — — EP disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 ARF6 3310/4885TNKS 531/4885TNKS2 932/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 ARF6 3310/4885TNKS 531/4885TNKS2 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback